Brain dopamine transporter: gender differences and effect of chronic haloperidol
Gender differences and the effect of chronic haloperidol on the rat brain dopamine transporter is reported. The density of striatal dopamine transporter sites labelled with [ 3H]GBR 12935, and of substantia nigra dopamine transporter mRNA measured by in situ hybridization were higher in female compa...
Gespeichert in:
| Veröffentlicht in: | Brain research 1995-09, Vol.692 (1), p.269-272 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 272 |
|---|---|
| container_issue | 1 |
| container_start_page | 269 |
| container_title | Brain research |
| container_volume | 692 |
| creator | Rivest, Robert Falardeau, Pierre Di Paolo, Thérèse |
| description | Gender differences and the effect of chronic haloperidol on the rat brain dopamine transporter is reported. The density of striatal dopamine transporter sites labelled with [
3H]GBR 12935, and of substantia nigra dopamine transporter mRNA measured by in situ hybridization were higher in female compared to male rats whereas striatal D2 specific binding labelled with [
3H]spiperone was not significantly higher. Daily haloperidol treatment (1 mg/kg, i.p.) for 21 days increased striatal [
3H]spiperone specific binding but left unchanged striatal [
3H]GBR 12935 binding density and affinity as well as substantia nigra dopamine transporter mRNA levels. A reduce clearance rate of dopamine in the striatum after acute and chronic haloperidol was previously reported; the present results indicate that this may occur without changes in the sites of dopamine transport or in gene expression of this transporter. |
| doi_str_mv | 10.1016/0006-8993(95)00611-S |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77740944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000689939500611S</els_id><sourcerecordid>16978118</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-35e277c8e887086734ccb3c771f654f9bdac05adb58f2bce7b111b0693b0213f3</originalsourceid><addsrcrecordid>eNqFkEtrFTEUgIMo9dr6DxSykFIXU5NJJo8uClrUFgoWquuQSU5sZO5kmswt9N83473cZbs653C-8-BD6AMlp5RQ8YUQIhqlNTvR3eeaU9rcvkIrqmTbiJaT12i1R96id6X8qyVjmhygA9VxxShfoZtv2cYR-zTZdRwBz9mOZUp5hnyG_8LoIWMfQ4AMo4OC7egx1NLNOAXs7nIao8N3dkgT5OjTcITeBDsUeL-Lh-jPj--_Ly6b618_ry6-XjeuXp4b1kErpVOglCRKSMad65mTkgbR8aB7bx3prO87FdregewppT0RmvWkpSywQ3S83TvldL-BMpt1LA6GwY6QNsVIKTnRnL8IUqGlolRVkG9Bl1MpGYKZclzb_GgoMYtxs-g0i06jO_PfuLmtYx93-zf9Gvx-aKe49j_t-rY4O4Qq2MWyx5gQkrAFO99iUKU9RMimuLg49zFX28an-PwfT2ldnIc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16978118</pqid></control><display><type>article</type><title>Brain dopamine transporter: gender differences and effect of chronic haloperidol</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Rivest, Robert ; Falardeau, Pierre ; Di Paolo, Thérèse</creator><creatorcontrib>Rivest, Robert ; Falardeau, Pierre ; Di Paolo, Thérèse</creatorcontrib><description>Gender differences and the effect of chronic haloperidol on the rat brain dopamine transporter is reported. The density of striatal dopamine transporter sites labelled with [
3H]GBR 12935, and of substantia nigra dopamine transporter mRNA measured by in situ hybridization were higher in female compared to male rats whereas striatal D2 specific binding labelled with [
3H]spiperone was not significantly higher. Daily haloperidol treatment (1 mg/kg, i.p.) for 21 days increased striatal [
3H]spiperone specific binding but left unchanged striatal [
3H]GBR 12935 binding density and affinity as well as substantia nigra dopamine transporter mRNA levels. A reduce clearance rate of dopamine in the striatum after acute and chronic haloperidol was previously reported; the present results indicate that this may occur without changes in the sites of dopamine transport or in gene expression of this transporter.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/0006-8993(95)00611-S</identifier><identifier>PMID: 8548314</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Animals ; Biological and medical sciences ; Brain Chemistry - drug effects ; Brain Chemistry - physiology ; Carrier Proteins - metabolism ; Dopamine - metabolism ; Dopamine Antagonists - pharmacology ; Dopamine Plasma Membrane Transport Proteins ; Dopamine receptor ; Dopamine transporter ; Dopamine Uptake Inhibitors - pharmacology ; Female ; Gender effect ; Haloperidol ; Haloperidol - pharmacology ; In Situ Hybridization ; Male ; Medical sciences ; Membrane Glycoproteins ; Membrane Transport Proteins ; Neostriatum - drug effects ; Neostriatum - metabolism ; Nerve Tissue Proteins ; Neuropharmacology ; Pharmacology. Drug treatments ; Piperazines - pharmacology ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, Dopamine D2 - drug effects ; Receptors, Dopamine D2 - metabolism ; RNA, Messenger - biosynthesis ; Sex Characteristics ; Spiperone - metabolism ; Substantia Nigra - drug effects ; Substantia Nigra - metabolism</subject><ispartof>Brain research, 1995-09, Vol.692 (1), p.269-272</ispartof><rights>1995 Elsevier Science B.V. All rights reserved</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-35e277c8e887086734ccb3c771f654f9bdac05adb58f2bce7b111b0693b0213f3</citedby><cites>FETCH-LOGICAL-c483t-35e277c8e887086734ccb3c771f654f9bdac05adb58f2bce7b111b0693b0213f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0006-8993(95)00611-S$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3667034$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8548314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rivest, Robert</creatorcontrib><creatorcontrib>Falardeau, Pierre</creatorcontrib><creatorcontrib>Di Paolo, Thérèse</creatorcontrib><title>Brain dopamine transporter: gender differences and effect of chronic haloperidol</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Gender differences and the effect of chronic haloperidol on the rat brain dopamine transporter is reported. The density of striatal dopamine transporter sites labelled with [
3H]GBR 12935, and of substantia nigra dopamine transporter mRNA measured by in situ hybridization were higher in female compared to male rats whereas striatal D2 specific binding labelled with [
3H]spiperone was not significantly higher. Daily haloperidol treatment (1 mg/kg, i.p.) for 21 days increased striatal [
3H]spiperone specific binding but left unchanged striatal [
3H]GBR 12935 binding density and affinity as well as substantia nigra dopamine transporter mRNA levels. A reduce clearance rate of dopamine in the striatum after acute and chronic haloperidol was previously reported; the present results indicate that this may occur without changes in the sites of dopamine transport or in gene expression of this transporter.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Brain Chemistry - drug effects</subject><subject>Brain Chemistry - physiology</subject><subject>Carrier Proteins - metabolism</subject><subject>Dopamine - metabolism</subject><subject>Dopamine Antagonists - pharmacology</subject><subject>Dopamine Plasma Membrane Transport Proteins</subject><subject>Dopamine receptor</subject><subject>Dopamine transporter</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Female</subject><subject>Gender effect</subject><subject>Haloperidol</subject><subject>Haloperidol - pharmacology</subject><subject>In Situ Hybridization</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins</subject><subject>Membrane Transport Proteins</subject><subject>Neostriatum - drug effects</subject><subject>Neostriatum - metabolism</subject><subject>Nerve Tissue Proteins</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - pharmacology</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Dopamine D2 - drug effects</subject><subject>Receptors, Dopamine D2 - metabolism</subject><subject>RNA, Messenger - biosynthesis</subject><subject>Sex Characteristics</subject><subject>Spiperone - metabolism</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia Nigra - metabolism</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtrFTEUgIMo9dr6DxSykFIXU5NJJo8uClrUFgoWquuQSU5sZO5kmswt9N83473cZbs653C-8-BD6AMlp5RQ8YUQIhqlNTvR3eeaU9rcvkIrqmTbiJaT12i1R96id6X8qyVjmhygA9VxxShfoZtv2cYR-zTZdRwBz9mOZUp5hnyG_8LoIWMfQ4AMo4OC7egx1NLNOAXs7nIao8N3dkgT5OjTcITeBDsUeL-Lh-jPj--_Ly6b618_ry6-XjeuXp4b1kErpVOglCRKSMad65mTkgbR8aB7bx3prO87FdregewppT0RmvWkpSywQ3S83TvldL-BMpt1LA6GwY6QNsVIKTnRnL8IUqGlolRVkG9Bl1MpGYKZclzb_GgoMYtxs-g0i06jO_PfuLmtYx93-zf9Gvx-aKe49j_t-rY4O4Qq2MWyx5gQkrAFO99iUKU9RMimuLg49zFX28an-PwfT2ldnIc</recordid><startdate>19950918</startdate><enddate>19950918</enddate><creator>Rivest, Robert</creator><creator>Falardeau, Pierre</creator><creator>Di Paolo, Thérèse</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19950918</creationdate><title>Brain dopamine transporter: gender differences and effect of chronic haloperidol</title><author>Rivest, Robert ; Falardeau, Pierre ; Di Paolo, Thérèse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-35e277c8e887086734ccb3c771f654f9bdac05adb58f2bce7b111b0693b0213f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Brain Chemistry - drug effects</topic><topic>Brain Chemistry - physiology</topic><topic>Carrier Proteins - metabolism</topic><topic>Dopamine - metabolism</topic><topic>Dopamine Antagonists - pharmacology</topic><topic>Dopamine Plasma Membrane Transport Proteins</topic><topic>Dopamine receptor</topic><topic>Dopamine transporter</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Female</topic><topic>Gender effect</topic><topic>Haloperidol</topic><topic>Haloperidol - pharmacology</topic><topic>In Situ Hybridization</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins</topic><topic>Membrane Transport Proteins</topic><topic>Neostriatum - drug effects</topic><topic>Neostriatum - metabolism</topic><topic>Nerve Tissue Proteins</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - pharmacology</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Dopamine D2 - drug effects</topic><topic>Receptors, Dopamine D2 - metabolism</topic><topic>RNA, Messenger - biosynthesis</topic><topic>Sex Characteristics</topic><topic>Spiperone - metabolism</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia Nigra - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rivest, Robert</creatorcontrib><creatorcontrib>Falardeau, Pierre</creatorcontrib><creatorcontrib>Di Paolo, Thérèse</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rivest, Robert</au><au>Falardeau, Pierre</au><au>Di Paolo, Thérèse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brain dopamine transporter: gender differences and effect of chronic haloperidol</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1995-09-18</date><risdate>1995</risdate><volume>692</volume><issue>1</issue><spage>269</spage><epage>272</epage><pages>269-272</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>Gender differences and the effect of chronic haloperidol on the rat brain dopamine transporter is reported. The density of striatal dopamine transporter sites labelled with [
3H]GBR 12935, and of substantia nigra dopamine transporter mRNA measured by in situ hybridization were higher in female compared to male rats whereas striatal D2 specific binding labelled with [
3H]spiperone was not significantly higher. Daily haloperidol treatment (1 mg/kg, i.p.) for 21 days increased striatal [
3H]spiperone specific binding but left unchanged striatal [
3H]GBR 12935 binding density and affinity as well as substantia nigra dopamine transporter mRNA levels. A reduce clearance rate of dopamine in the striatum after acute and chronic haloperidol was previously reported; the present results indicate that this may occur without changes in the sites of dopamine transport or in gene expression of this transporter.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>8548314</pmid><doi>10.1016/0006-8993(95)00611-S</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-8993 |
| ispartof | Brain research, 1995-09, Vol.692 (1), p.269-272 |
| issn | 0006-8993 1872-6240 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77740944 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Animals Biological and medical sciences Brain Chemistry - drug effects Brain Chemistry - physiology Carrier Proteins - metabolism Dopamine - metabolism Dopamine Antagonists - pharmacology Dopamine Plasma Membrane Transport Proteins Dopamine receptor Dopamine transporter Dopamine Uptake Inhibitors - pharmacology Female Gender effect Haloperidol Haloperidol - pharmacology In Situ Hybridization Male Medical sciences Membrane Glycoproteins Membrane Transport Proteins Neostriatum - drug effects Neostriatum - metabolism Nerve Tissue Proteins Neuropharmacology Pharmacology. Drug treatments Piperazines - pharmacology Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Rats Rats, Sprague-Dawley Receptors, Dopamine D2 - drug effects Receptors, Dopamine D2 - metabolism RNA, Messenger - biosynthesis Sex Characteristics Spiperone - metabolism Substantia Nigra - drug effects Substantia Nigra - metabolism |
| title | Brain dopamine transporter: gender differences and effect of chronic haloperidol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A57%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brain%20dopamine%20transporter:%20gender%20differences%20and%20effect%20of%20chronic%20haloperidol&rft.jtitle=Brain%20research&rft.au=Rivest,%20Robert&rft.date=1995-09-18&rft.volume=692&rft.issue=1&rft.spage=269&rft.epage=272&rft.pages=269-272&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/0006-8993(95)00611-S&rft_dat=%3Cproquest_cross%3E16978118%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16978118&rft_id=info:pmid/8548314&rft_els_id=000689939500611S&rfr_iscdi=true |